Dental pulp capping: effect of Emdogain Gel on experimentally exposed human pulps.
OBJECTIVE
To investigate the effect of Emdogain Gel (Biora AB, Malmo, Sweden), consisting of a enamel matrix derivative (EMD) in a propylene glycol alginate (PGA) vehicle, on experimentally exposed human pulps and to register postoperative symptoms.


METHODS
Nine pairs of contralateral premolars scheduled for extraction on orthodontic indications were included. Following a superficial pulp amputation performed with a small (016) diamond bur, either EMDgel or a mix of calcium hydroxide and sterile saline was placed at random in contact with the pulp wound. The subjects made records of symptoms and were also interviewed about pain/discomfort by a blinded examiner. After 12 weeks the teeth were extracted, prepared and subjected to light microscopic examination in which the inflammation and newly formed hard tissue in the pulp were analysed. Immunohistochemistry was performed using affinity-purified rabbit anti-EMD polyclonal antibodies.


RESULTS
Postoperative symptoms were less frequent in the EMDgel-treated than in the calcium hydroxide-treated teeth, especially during the first six weeks. In the EMDgel-treated teeth, new tissue partly filled the space initially occupied by the gel and hard tissue was formed alongside the exposed dentine surfaces and in patches in the adjacent pulp tissue. EMD was detected in the areas where new hard tissue had been formed. The wound area of the EMDgel-treated teeth exhibited inflammation in the majority of the teeth whereas less inflammation was seen in the calcium hydroxide-treated teeth where the hard tissue was formed as a bridge.


CONCLUSIONS
In the EMDgel-treated teeth, postoperative symptoms were less frequent and the amount and pattern of hard tissue formation were markedly different than in the teeth treated with calcium hydroxide. However, the operative procedure and the formulation with EMD in a PGA vehicle do not seem to be effective for the formation of a hard tissue barrier.
Olsson
H
H
Department of Endodontics, Faculty of Odontology, Malmö University, Sweden. helena.olsson@od.mah.se
Davies
J R
JR
Holst
K E
KE
Schröder
U
U
Petersson
K
K
D000293:Adolescent; D001641:Bicuspid; D002126:Calcium Hydroxide / Q000627:therapeutic use*; D002648:Child; D003746:Dental Enamel Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D003785:Dental Pulp Capping / Q000009:adverse effects / Q000379:methods*; D003809:Dentin, Secondary / Q000254:growth & development / Q000378:metabolism; D005782:Gels; D006801:Humans; D010149:Postoperative Pain / Q000209:etiology; D010865:Pilot Projects; D011671:Pulpitis / Q000209:etiology; D011672:Pulpotomy; D012387:Root Canal Filling Materials / Q000627:therapeutic use*; D016037:Single-Blind Method
D003746:Dental Enamel Proteins; D005782:Gels; D012387:Root Canal Filling Materials; C109069:enamel matrix proteins; D002126:Calcium Hydroxide